3D printing in Ophthalmology: From medical implants to personalised medicine.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Sep 2022
Historique:
received: 12 06 2022
revised: 26 07 2022
accepted: 04 08 2022
pubmed: 12 8 2022
medline: 14 9 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

3D printing was invented thirty years ago. However, its application in healthcare became prominent only in recent years to provide solutions for drug delivery and clinical challenges, and is constantly evolving. This cost-efficient technique utilises biocompatible materials and is used to develop model implants to provide a greater understanding of human anatomy and diseases, and can be used for organ transplants, surgical planning and for the manufacturing of advanced drug delivery systems. In addition, 3D printed medical devices and implants can be customised for each patient to provide a more tailored treatment approach. The advantages and applications of 3D printing can be used to treat patients with different eye conditions, with advances in 3D bioprinting offering novel therapy applications in ophthalmology. The purpose of this review paper is to provide an in-depth understanding of the applications and advantages of 3D printing in treating different ocular conditions in the cornea, glaucoma, retina, lids and orbits.

Identifiants

pubmed: 35952803
pii: S0378-5173(22)00648-2
doi: 10.1016/j.ijpharm.2022.122094
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

122094

Subventions

Organisme : Medical Research Council
ID : MR/T027932/1
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Greymi Tan (G)

Faculty of Life Sciences & Medicine, King's College London, London, SE1 7EH, UK.

Nicole Ioannou (N)

Faculty of Life Sciences & Medicine, King's College London, London, SE1 7EH, UK.

Essyrose Mathew (E)

School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.

Aristides D Tagalakis (AD)

Department of Biology, Edge Hill University, Ormskirk, L39 4QP, UK.

Dimitrios A Lamprou (DA)

School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK. Electronic address: d.lamprou@qub.ac.uk.

Cynthia Yu-Wai-Man (C)

Faculty of Life Sciences & Medicine, King's College London, London, SE1 7EH, UK. Electronic address: cynthia.yu-wai-man@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH